Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Wiviott, SD; Raz, I; Bonaca, MP; Mosenzon, O; Kato, ET; Cahn, A; Silverman, MG; Zelniker, TA; Kuder, JF; Murphy, SA; Bhatt, DL; Leiter, LA; McGuire, DK; Wilding, JPH; Ruff, CT; Gause-Nilsson, IAM; Fredriksson, M; Johansson, PA; Langkilde, AM; Sabatine, MS; DECLARE–TIMI 58 Investigators.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med. 2019; 380(4): 347-357.
Doi: 10.1056/NEJMoa1812389
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Mitglieder der Med Uni Graz:
- Bugger Heiko Matthias
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. We randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease to receive either dapagliflozin or placebo. The primary safety outcome was a composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke. The primary efficacy outcomes were MACE and a composite of cardiovascular death or hospitalization for heart failure. Secondary efficacy outcomes were a renal composite (≥40% decrease in estimated glomerular filtration rate to <60 ml per minute per 1.73 m2 of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes) and death from any cause. We evaluated 17,160 patients, including 10,186 without atherosclerotic cardiovascular disease, who were followed for a median of 4.2 years. In the primary safety outcome analysis, dapagliflozin met the prespecified criterion for noninferiority to placebo with respect to MACE (upper boundary of the 95% confidence interval [CI], <1.3; P<0.001 for noninferiority). In the two primary efficacy analyses, dapagliflozin did not result in a lower rate of MACE (8.8% in the dapagliflozin group and 9.4% in the placebo group; hazard ratio, 0.93; 95% CI, 0.84 to 1.03; P=0.17) but did result in a lower rate of cardiovascular death or hospitalization for heart failure (4.9% vs. 5.8%; hazard ratio, 0.83; 95% CI, 0.73 to 0.95; P=0.005), which reflected a lower rate of hospitalization for heart failure (hazard ratio, 0.73; 95% CI, 0.61 to 0.88); there was no between-group difference in cardiovascular death (hazard ratio, 0.98; 95% CI, 0.82 to 1.17). A renal event occurred in 4.3% in the dapagliflozin group and in 5.6% in the placebo group (hazard ratio, 0.76; 95% CI, 0.67 to 0.87), and death from any cause occurred in 6.2% and 6.6%, respectively (hazard ratio, 0.93; 95% CI, 0.82 to 1.04). Diabetic ketoacidosis was more common with dapagliflozin than with placebo (0.3% vs. 0.1%, P=0.02), as was the rate of genital infections that led to discontinuation of the regimen or that were considered to be serious adverse events (0.9% vs. 0.1%, P<0.001). In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure. (Funded by AstraZeneca; DECLARE-TIMI 58 ClinicalTrials.gov number, NCT01730534 .).
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Benzhydryl Compounds - adverse effects
- Benzhydryl Compounds - therapeutic use
- Cardiovascular Diseases - etiology
- Cardiovascular Diseases - mortality
- Cardiovascular Diseases - prevention & control
- Diabetes Mellitus, Type 2 - complications
- Diabetes Mellitus, Type 2 - drug therapy
- Female -
- Glucosides - adverse effects
- Glucosides - therapeutic use
- Heart Failure - epidemiology
- Hospitalization - statistics & numerical data
- Humans -
- Male -
- Middle Aged -
- Sodium-Glucose Transporter 2 Inhibitors - adverse effects
- Sodium-Glucose Transporter 2 Inhibitors - therapeutic use